• 1
    Lipsky PE, Tao XL. A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 1997; 26: 71323.
  • 2
    Tao XL, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 2000; 26: 2950.
  • 3
    Tao X, Cush JJ, Garret M, Lipsky PE. A phase I study of ethyl acetate extract of the Chinese antirheumatic herb Tripterygium wilfordii Hook F in rheumatoid arthritis. J Rheumatol 2001; 28: 21607.
  • 4
    Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002; 46: 173543.
  • 5
    Tao X, Davis LS, Lipsky PE. Effects of an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F on human immune responsiveness. Arthritis Rheum 1991; 34: 127481.
  • 6
    Tao X, Cai JJ, Lipsky PE. The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook F. J Pharmacol Exp Ther 1995; 272: 130512.
  • 7
    Tao X, Schulze-Koops H, Ma L, Cai J, Mao Y, Lipsky PE. Effects of Tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 1998; 41: 1308.
  • 8
    Tao X, Ma L, Mao Y, Lipsky PE. Suppression of carrageenan-induced inflammation in vivo by an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F. Inflamm Res 1999; 48: 13948.
  • 9
    Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 10942.
  • 10
    Stefanovic-Racic M, Stadler J, Evans CH. Nitric oxide and arthritis. Arthritis Rheum 1993; 36: 103644.
  • 11
    Jang D, Murrell GA. Nitric oxide in arthritis. Free Radic Biol Med 1998; 24: 15119.
  • 12
    Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide in rheumatic diseases. Ann Rheum Dis 1992; 51: 121922.
  • 13
    Ueki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996; 23: 2306.
  • 14
    Stichtenoth DO, Fauler J, Zeidler H, Frolich JC. Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone. Ann Rheum Dis 1995; 54: 8204.
  • 15
    Stichtenoth DO, Frolich JC. Nitric oxide and inflammatory joint diseases. Br J Rheumatol 1998; 37: 24657.
  • 16
    Grabowski PS, Wright PK, van' t Hof RJ, Helfrich MH, Ohshima H, Ralston SH. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1997; 36: 6515.
  • 17
    Pham TN, Rahman P, Tobin YM, Khraishi MM, Hamilton SF, Alderdice C, et al. Elevated serum nitric oxide levels in patients with inflammatory arthritis associated with co-expression of inducible nitric oxide synthase and protein kinase C-η in peripheral blood monocyte-derived macrophages. J Rheumatol 2003; 30: 252934.
  • 18
    Yki-Jarvinen H, Bergholm R, Leirisalo-Repo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 6304.
  • 19
    Tao X, Ma L, Cai J, Mao Y, Taurog J, Lipsky PE. Treatment with an ethyl acetate extract of Tripterygium wilfordii Hook F improves joint inflammation in HLA B27-transgenic rats [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S298.
  • 20
    Cai JJ, Tao XL, Lipsky PE. High performance liquid chromatography determination of triptolide and tripdiolide in acetate extract of Tripterygium wilfordii Hook F. J Liquid Chromat 1994; 17: 447987.
  • 21
    Mao YP, Tao XL, Lipsky PE. Analysis of the stability and degradation products of triptolide. J Pharm Pharmacol 2000; 52: 312.
  • 22
    Wernersson S, Kleinau S, Heyman B. Immune complex-mediated enhancement of antibody responses without induction of delayed-type hypersensitivity. Scand J Immunol 2000; 52: 5639.
  • 23
    Khair-El-Din T, Sicher SC, Vazquez MA, Chung GW, Stallworth KA, Kitamura K, et al. Transcription of the murine iNOS gene is inhibited by docosahexaenoic acid, a major constituent of fetal and neonatal sera as well as fish oils. J Exp Med 1996; 183: 12426.
  • 24
    Dlaska M, Weiss G. Central role of transcription factor NF-IL6 for cytokine and iron-mediated regulation of murine inducible nitric oxide synthase expression. J Immunol 1999; 162: 61717.
  • 25
    Kristof AS, Marks-Konczalik J, Moss J. Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem 2001; 276: 844552.
  • 26
    Sawada T, Falk LA, Rao P, Murphy WJ, Pluznik DH. IL-6 induction of protein-DNA complexes via a novel regulatory region of the inducible nitric oxide synthase gene promoter: role of octamer binding proteins. J Immunol 1997; 158: 526776.
  • 27
    Von Knethen A, Callsen D, Brune B. NF-κB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264.7 macrophages. Mol Biol Cell 1999; 10: 36172.
  • 28
    De Vera ME, Taylor BS, Wang Q, Shapiro RA, Billiar TR, Geller DA. Dexamethasone suppresses iNOS gene expression by upregulating I-κBα and inhibiting NF-κB. Am J Physiol 1997; 273: G12906.
  • 29
    Matsumura M, Kakishita H, Suzuki M, Banba N, Hattori Y. Dexamethasone suppresses iNOS gene expression by inhibiting NF-κB in vascular smooth muscle cells. Life Sci 2001; 69: 106777.
  • 30
    Subramaniam N, Cairns W, Okret S. Glucocorticoids repress transcription from a negative glucocorticoid response element recognized by two homeodomain-containing proteins, Pbx and Oct-1. J Biol Chem 1998; 273: 2356774.
  • 31
    Lee BS, Kim YM, Kang HS, Kim HM, Pyun KH, Choi I. Octamer binding protein-1 is involved in inhibition of inducible nitric oxide synthase expression by exogenous nitric oxide in murine liver cells. J Biochem (Tokyo) 2001; 129: 7786.
  • 32
    Liu XK, Abernethy DR, Andrawis NS. Nitric oxide inhibits Oct-1 DNA binding activity in cultured vascular smooth muscle cells. Life Sci 1998; 62: 73949.
  • 33
    Beri A, Singh S, Gupta A, Khullar M. Comparison of serum nitric oxide levels in active juvenile rheumatoid arthritis with those of patients in remission. Rheumatol Int 2003;Oct 31 [Epub ahead of print].
  • 34
    Lamarque D, Nhieu JT, Breban M, Bernardeau C, Martin-Garcia N, Szepes Z, et al. Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic feature of ankylosing spondylitis. J Rheumatol 2003; 30: 242836.
  • 35
    Albina JE, Abate JA, Henry WL Jr. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: role of IFN-γ in the induction of the nitric oxide-synthesizing pathway. J Immunol 1991; 147: 1448.
  • 36
    Marcinkiewicz J, Grabowska A, Chain BM. Is there a role for nitric oxide in regulation of T cell secretion of IL-2? J Immunol 1996; 156: 461721.
  • 37
    Chu SC, Marks-Konczalik J, Wu HP, Banks TC, Moss J. Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. Biochem Biophys Res Commun 1998; 248: 8718.
  • 38
    Zhang X, Laubach VE, Alley EW, Edwards KA, Sherman PA, Russell SW, et al. Transcriptional basis for hyporesponsiveness of the human inducible nitric oxide synthase gene to lipopolysaccharide/interferon-γ. J Leukoc Biol 1996; 59: 57585.
  • 39
    Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon-γ and bacterial lipopolysaccharide. J Exp Med 1993; 177: 177984.
  • 40
    Nunokawa Y, Ishida N, Tanaka S. Promoter analysis of human inducible nitric oxide synthase gene associated with cardiovascular homeostasis. Biochem Biophys Res Commun 1994; 200: 8027.
  • 41
    Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, et al. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon γ and lipopolysaccharide. Proc Natl Acad Sci U S A 1993; 90: 97304.
  • 42
    Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-κB transcriptional activation. J Biol Chem 1999; 274: 1344350.
  • 43
    Segil N, Roberts SB, Heintz N. Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA binding activity. Science 1991; 254: 18146.